A company called Astrogenetix has started the approval process for putting their salmonella vaccine through the clinical trial wringer. The outfit, based in Austin, Texas developed its vaccine through research carried out on NASA's space shuttle missions.
Scientists have long known that bacteria and viruses grow more rapidly and virulently in space. Astrogenetix took advantage of that fast-growing, super-active state to home in on the salmonella genes responsible for infectiousness, and then removed said genes to create a weak vaccine strain.
"We don't fully understand why these bugs show increased virulence," said Astrogenetix CEO John Porter in a SPACE.com interview. "But when you see increased virulence it helps you to target potential therapeutic candidates at a particular disease."
The company hopes for its vaccine to enter human clinical trials next year, and plans to continue more experiments on the remaining space shuttle missions and the International Space Station. Next up in its sights: deadly MRSA bacteria that plague hospitals and have grown resistant to antibiotics.[via SPACE.com]
138 years of Popular Science at your fingertips.
Each issue has been completely reimagined for your iPad. See our amazing new vision for magazines that goes far beyond the printed page
Stay up to date on the latest news of the future of science and technology from your iPhone or Android phone with full articles, images and offline viewing
Featuring every article from the magazine and website, plus links from around the Web. Also see our PopSci DIY feed
Science is reinventing play, from extreme sports to gamification to ridiculous roller coasters to the playgrounds of tomorrow, and this issue is chock full of fun. Also, on a less fun note: Did global warming destroy my hometown?